NVO
NYSE · Healthcare
Novo Nordisk A/S
$47.47
+0.05 (+0.11%)
NVO News30 articles
Novo Nordisk B Shares Surge on South African Court Ruling Against Compounder
Novo Nordisk B shares surged 9.9% in three sessions after a South African court halted iDexis from supplying compounded semaglutide, potentially shifting demand to Novo.
Viking Therapeutics Surges on Obesity Drug Hopes
Viking Therapeutics shares climbed 6% to $34.30 as investors bet on upcoming Phase 3 data for its obesity drug VK2735, expected in Q3 2026.
Pfizer Shares Slip as CFO Departure Rattles Investors; 2026 Outlook Intact
Pfizer shares fell 2.7% to $25.21 after CFO Dave Denton said he will leave in August, reigniting investor concerns over succession and obesity-drug competition.
Novo Nordisk Shares Rally as Healthcare Sector Lifts OMXC25
Novo Nordisk B shares rose 5% to 294.4 Danish crowns, leading the OMXC25 higher as healthcare stocks gained. The rally came amid a cyber incident and ongoing competition with Eli Lilly in oral obesity drugs.
Pfizer CFO Departure Raises Growth Strategy Questions, Stock Slips 3%
Pfizer shares slid 3.2% after announcing CFO Dave Denton's departure, intensifying investor scrutiny of the company's 2026 guidance and obesity drug strategy.
Hims & Hers Health Surges on Weight-Loss Drug Strategy Optimism
Hims & Hers Health (HIMS) shares rallied 6.6% to $28.98 on heavy volume, bucking a tech selloff, as investors refocus on the company's weight-loss drug scaling potential after a challenging quarter.
Pfizer Stock Dips Despite FDA Nod for Hemophilia Drug Hympavzi
Pfizer shares fell premarket despite FDA approval for hemophilia drug Hympavzi, as investors focus on slower obesity drug progress and pipeline challenges.
Novo Nordisk Shares Slide 4% Despite Wegovy Pill Prescriptions Surpassing 3 Million
Novo Nordisk shares dropped over 4% despite the Wegovy pill hitting 3 million U.S. prescriptions, as investors weighed profit margins against fierce competition from Eli Lilly and AstraZeneca.
Eli Lilly Faces Market Test After Retatrutide Shows Broad Health Benefits
Eli Lilly's new obesity drug retatrutide showed 28.3% weight loss and improvements in sleep apnea and knee pain. The stock faces a key test Monday amid competing data from rivals.
Eli Lilly Hits Record Close on Retatrutide Data; Market Awaits Monday
Eli Lilly shares closed at a record $1,131.42 Friday after retatrutide data showed significant reductions in sleep apnea and knee osteoarthritis pain. Investors eye Monday's trade for market reaction.
Veru Stock Soars on Novo Nordisk Supply Deal for Obesity Trial
Veru shares jumped 88% to $4.23 after Novo Nordisk agreed to supply Wegovy for Veru's Phase 2b obesity trial. Analysts see it as a validation, but risks remain with trial endpoints and a 60-day exit clause.
Veru Stock Surges on Novo Nordisk Obesity Trial Collaboration
Veru shares surged 112% to $4.78 after Novo Nordisk will provide Wegovy for Veru's Phase 2b obesity trial. Analysts kept $24-$25 targets, but Veru warned of trial risks and reimbursement challenges.
Hims Completes $1.15B Eucalyptus Acquisition, Shares Dip Slightly
Hims & Hers shares fell 0.9% after completing the $1.15 billion Eucalyptus acquisition, gaining 850,000 customers and international reach, but facing execution risks and U.S. weight-loss drug plan shifts.
Lilly Expands Vaccine Portfolio with $3.83B Triple Acquisition
Eli Lilly acquires Curevo, LimmaTech, and Vaccine Company for up to $3.83B, gaining vaccine candidates for shingles, staph, and Epstein-Barr virus. Shares rose 5%.
CPI Surge and Oil Spike End Wall Street's Record Rally
U.S. stocks retreated Tuesday after a hotter-than-expected April CPI report and a surge in oil prices to $107.72 halted Wall Street's record run. Markets now price zero Fed rate cuts in 2026.
Hims & Hers Stock Plunges on Q1 Loss, Weight-Loss Strategy Shift
Hims & Hers shares dropped 10% on a surprise Q1 net loss and revenue miss. The company raised its 2026 sales forecast but cut profit outlook amid a costly shift to branded weight-loss drugs.
Novo Nordisk Stock Climbs as Ozempic Study Shows 15.4% Weight Loss in Seniors
Novo Nordisk B shares gained 3.75% in Copenhagen after a pooled analysis revealed semaglutide 2.4 mg resulted in 15.4% weight loss in older adults, reinforcing the company's obesity portfolio.
Hims & Hers Earnings: Weight-Loss Strategy in Focus as GLP-1 Shift Unfolds
Hims & Hers Health reports Q1 earnings Monday after close, with Wall Street expecting ~$617M revenue. The key focus: how its weight-loss business performs after shifting from compounded GLP-1 drugs to FDA-approved options from Novo Nordisk.
Hims & Hers Health Faces GLP-1 Pivot Ahead of Q1 Earnings
Hims & Hers Health shares surged 10.2% ahead of Q1 earnings, as investors watch the company's pivot from compounded to branded GLP-1 drugs amid FDA regulatory changes.
Novo Nordisk Shares Surge on Strong Wegovy Pill Sales, Upgraded 2026 Outlook
Novo Nordisk raised its 2026 guidance after Wegovy pill prescriptions topped 2 million, sending shares up 9.2%. The company now expects a smaller decline in sales and profit this year.
Dow Surges 700 Points as Earnings Power Stocks Toward Best Month Since 2020
The Dow Jones surged 700 points on Thursday, leading a broad rally as strong corporate earnings pushed major indexes toward their best monthly gains since 2020, shrugging off oil price concerns.
Eli Lilly Lifts 2026 Guidance After GLP-1 Sales Surge 56% in Q1
Eli Lilly boosted its 2026 revenue outlook by $2 billion after Q1 sales jumped 56% to $19.8 billion, propelled by Mounjaro and Zepbound. The company also launched oral GLP-1 pill Foundayo.
Hims & Hers Surges on JPMorgan Upgrade and GLP-1 Expansion
Hims & Hers stock jumped 9% after JPMorgan gave an overweight rating and $35 target. The company now offers Eli Lilly's Zepbound and Foundayo through LillyDirect.
Lilly's Oral Obesity Drug Foundayo Trails Novo Nordisk's Wegovy in Early Prescription Data
Eli Lilly's Foundayo prescriptions hit 3,707 in week two, well behind Novo Nordisk's Wegovy. Lilly shares dropped 4%, while Novo gained 6%. Analysts advise caution on early figures.
Novo Nordisk Wegovy Pill Prescriptions Surge Past Eli Lilly's Foundayo in Early Launch Race
Novo Nordisk's Wegovy pill recorded 18,410 U.S. prescriptions in its second week, far outpacing Eli Lilly's Foundayo at 3,707, according to IQVIA data. Novo shares rose, Lilly fell.
Hims Expands Branded GLP-1 Access with Lilly's Zepbound and Foundayo
Hims & Hers Health now offers Eli Lilly's Zepbound and Foundayo via LillyDirect, broadening its branded GLP-1 lineup amid a competitive cash-pay market.
Amazon's GLP-1 Launch Pressures Hims & Hers, Telehealth Rivals
Shares of Hims & Hers Health dropped Tuesday after Amazon launched a GLP-1 weight-management program, heightening competition in the telehealth sector. The company is pivoting from compounded drugs to FDA-approved branded medications.
Pfizer Gains on FDA Priority Review for Padcev as Pipeline Pivots Post-COVID
Pfizer shares advanced after the FDA granted priority review for its Padcev bladder cancer therapy, setting an August decision. Investors await Q1 results to gauge progress in oncology and obesity drugs against fading COVID sales.
Major Investors Reduce Pfizer Holdings Amid Growth Transition
Three institutional investors trimmed their Pfizer positions by a combined 740,174 shares in the fourth quarter, filings show, as the pharmaceutical giant navigates its post-pandemic transition.
Pfizer Shares Reach New Peak Amid Divergent Views on Future Growth
Pfizer shares surged to a 52-week high of $28.30, driven by robust quarterly results and promising oncology data. Analysts remain divided on whether the stock's rally is sustainable given looming growth challenges.